Regeneron Pharmaceuticals: An Insight Into Dupixent’s Market Presence & Recent Oncology Portfolio Expansion! 

Regeneron Pharmaceuticals’ first quarter 2025 results illustrate a multifaceted performance landscape, marked by both promising advancements and significant hurdles across its drug portfolio. Starting with EYLEA, the company saw U.S. net sales of $736 million, a decrease of 39% compared to the prior year, amid heightened competition from low-cost, off-label Avastin, influenced by patient affordability issues due to a funding gap at co-pay assistance foundations. While EYLEA HD sales increased by 54% year-over-year, its sequential growth was stagnant. The market contraction for the anti-VEGF category was cited as a challenge, resulting in decreased sales and lower inventory levels. Regeneron also faced a setback with the FDA’s issuance of a Complete Response Letter concerning the EYLEA HD pre-filled syringe, highlighting regulatory hurdles that could affect market dynamics.